- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00150462
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
California
-
Beverly Hills, California, Stati Uniti, 90211-1850
- Tower Cancer Research Foundation
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
New York
-
New York, New York, Stati Uniti, 10021
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Stati Uniti, 10021
- Weil Medical College of Cornell University
-
New York, New York, Stati Uniti, 10032
- Herbert Irving Comprehensive Cancer Center, Columbia University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Written informed consent in accordance with federal, local, and institutional guidelines
- Males and females ≥18 years of age
Histologically confirmed diagnosis of one of the hematologic malignancies below:
- Multiple myeloma (MM)
- Non-Hodgkin's lymphoma (NHL)
- Waldenström's Macroglobulinemia (WM)
- Hodgkin's disease (HD)
- Subjects who are refractory or relapsed following at least two prior therapies
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
- Adequate cardiovascular function without symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction in the previous six months
- Adequate hepatic function, with bilirubin < 2.0 times the upper limit of normal, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of < 3.0 times the upper limit of normal
Total white blood cell (WBC) count ≥ 2,000/mm³, absolute neutrophil count (ANC) ≥ 1000/mm³, hemoglobin ≥ 8.0 g/dL, and platelet count ≥ 50,000/mm³
- Screening ANC should be independent of granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support for ≥ 1 week and of pegylated G-CSF for ≥ 2 weeks)
- Subjects receiving supportive care including erythropoietin, darbepoetin and/or bisphosphonates can continue to do so, but must be transfusion independent; subjects receiving erythropoietic support must remain on the same dose for the first 28 days of study participation
- An estimated creatinine clearance of ≥ 30 mL/min, calculated using the formula of Cockroft and Gault
- Serum creatinine ≤ 2.0 mg/dL
- Uric acid, if elevated, must be corrected to within laboratory normal range prior to dosing
- Female subjects of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test. Male subjects must use an effective barrier method of contraception throughout the study and for three months following the last dose if sexually active with a female of child-bearing potential.
Exclusion Criteria:
- Female subjects who are pregnant or lactating
- Subjects who are transfusion dependent
- Subjects with NHL or HL who have received steroid therapy in the previous seven days
- Subjects with MM or Waldenström's Macroglobulinemia who have received steroid therapy in the previous three weeks, except for MM subjects in the Carfilzomib + DEX Expansion Cohort, where previous treatment with dexamethasone will be allowed. The dose and schedule of administration of dexamethasone will be adjusted to that used in the protocol
- Radiation, chemotherapy, or immunotherapy in the previous four weeks, or subjects who, in the judgment of the Investigator, have not recovered from the effects of previous therapy
- For the Dose Escalation period, subjects who have received prior radioimmunotherapy with anti-cluster of differentiation (CD)20 monoclonal antibodies such as Bexxar® or Zevalin®; subjects treated with these products will be allowed in the Dose Expansion period
- Subjects who have received allogeneic stem cell transplant therapy
- Subjects with NHL or HL who have received autologous stem cell transplant therapy and have relapsed within 100 days of therapy
- Rituxan therapy within three months before Day 1 unless there is evidence of disease progression
- Major surgery within three weeks before Day 1
- Congestive heart failure (CHF) (New York Heart Association class III to IV)
- Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
- Subjects who are known or suspected of having human immunodeficiency virus (HIV) infection or who are HIV seropositive
- Active hepatitis A, B, or C infection; or positive for Hepatitis C ribonucleic acid (RNA) or hepatitis B antigen
- Non-hematologic malignancy within the past three years except a) adequately treated basal cell or squamous cell skin cancer, b) carcinoma in situ of the cervix, or c) prostate cancer with stable prostate specific antigen (PSA) levels for three years
- Subjects with treatment-related myelodysplastic disorder
- Subjects with known brain metastasis (active central nervous system [CNS] disease only)
- Serious psychiatric or medical conditions that could interfere with treatment
- Participation in an investigational therapeutic study within one month prior to Day 1
- Significant neurotoxicity (Grade 2 or higher with pain) at the time of study initiation
- Concurrent therapy with approved or investigative anticancer therapeutics
- Subjects with previous hypersensitivity to bortezomib injection
- Subjects with contraindications to receiving allopurinol
- Subjects in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g., due to pre-existing pulmonary, cardiac, or renal impairment
- Subjects with known or suspected amyloidosis
- Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: CFZ 1.2 mg/m²
Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
|
Administered as an IV bolus dose
Altri nomi:
|
Sperimentale: CFZ 2.4 mg/m²
Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
|
Administered as an IV bolus dose
Altri nomi:
|
Sperimentale: CFZ 4.0 mg/m²
Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
|
Administered as an IV bolus dose
Altri nomi:
|
Sperimentale: CFZ 6.0 mg/m²
Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
|
Administered as an IV bolus dose
Altri nomi:
|
Sperimentale: CFZ 8.4 mg/m²
Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
|
Administered as an IV bolus dose
Altri nomi:
|
Sperimentale: CFZ 11.0 mg/m²
Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
|
Administered as an IV bolus dose
Altri nomi:
|
Sperimentale: CFZ 15.0 mg/m²
Participants received carfilzomib 115.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
|
Administered as an IV bolus dose
Altri nomi:
|
Sperimentale: CFZ 20.0 mg/m²
Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
|
Administered as an IV bolus dose
Altri nomi:
|
Sperimentale: CFZ 27.0 mg/m²
Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
|
Administered as an IV bolus dose
Altri nomi:
|
Sperimentale: CFZ 20/27 mg/m²
Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.
|
Administered as an IV bolus dose
Altri nomi:
|
Sperimentale: CFZ 20/27 mg/m² + DEX
Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.
Participants also received 20 mg dexamethasone (DEX) administered before each dose of carfilzomib (i.e.
40 mg weekly).
|
Administered as an IV bolus dose
Altri nomi:
Administered orally prior to carfilzomib
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Participants With Dose-limiting Toxicities (DLTs)
Lasso di tempo: 28 days
|
A DLT was defined as any of the following occurring in the first 28 days of study participation: Nonhematologic:
Hematologic:
Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 3.0. |
28 days
|
Maximum Observed Plasma Concentration of Carfilzomib (Cmax)
Lasso di tempo: Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
|
Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
|
|
Time to Maximum Observed Plasma Concentration of Carfilzomib (Tmax)
Lasso di tempo: Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
|
Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
|
|
Area Under the Concentration-time Curve to Last Measureable Timepoint (AUClast) for Carfilzomib
Lasso di tempo: Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
|
Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
|
|
Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) for Carfilzomib
Lasso di tempo: Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
|
Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Best Clinical Response to Treatment
Lasso di tempo: From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
|
Disease response criteria for NHL were according to the International Working Group Criteria for Non-Hodgkin's Lymphoma. Disease response criteria for Multiple Myeloma were according to the European Group for Blood and Marrow Transplantation (EBMT). Disease response criteria for WM were according to the consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. The disease response criteria for Hodgkin's Lymphoma are defined as follows:
Best clinical response is the best response observed from the start of study treatment until disease progression or death. |
From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
|
Duration of Response
Lasso di tempo: From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
|
Duration of objective response is defined as the time from the date of first documented assessment of clinical response (confirmed or unconfirmed complete response, partial response, or minimal response) to the date of documented assessment of progressive disease or death, whichever comes first, plus one day. Participants without tumor progression or death were censored at the date of their last valid clinical response assessment. Median duration of response was calculated using the Kaplan-Meier method. |
From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
|
Time to Progression
Lasso di tempo: From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
|
Time to progressive disease is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease, plus one day. Participants without tumor progression were censored at the date of their last clinical response assessment. Median time to progression was calculated using the Kaplan-Meier method. |
From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
|
Progression-free Survival
Lasso di tempo: From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
|
Progression-free survival is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease or death, whichever comes first, plus one day.
Participants without tumor progression or death were censored at the date of their last valid clinical response assessment.
Median progression-free survival was calculated using the Kaplan-Meier method.
|
From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattia cardiovascolare
- Malattie vascolari
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Neoplasie
- Malattie linfoproliferative
- Malattie linfatiche
- Disturbi immunoproliferativi
- Neoplasie per sede
- Malattie ematologiche
- Disturbi emorragici
- Disturbi emostatici
- Paraproteinemie
- Disturbi delle proteine del sangue
- Neoplasie, plasmacellule
- Linfoma
- Neoplasie ematologiche
- Mieloma multiplo
- Malattia di Hodgkin
- Macroglobulinemia di Waldenstrom
- Effetti fisiologici delle droghe
- Agenti autonomi
- Agenti del sistema nervoso periferico
- Agenti antinfiammatori
- Agenti antineoplastici
- Antiemetici
- Agenti gastrointestinali
- Glucocorticoidi
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Agenti antineoplastici, ormonali
- Desametasone
Altri numeri di identificazione dello studio
- PX-171-002
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Carfilzomib
-
Ajai ChariAmgenCompletatoMieloma multiplo refrattario | Mieloma multiplo recidivatoStati Uniti
-
AmgenCompletatoMieloma multiploStati Uniti, Canada
-
M.D. Anderson Cancer CenterOnyx Therapeutics, Inc.Terminato
-
AmgenCompletatoMieloma multiploStati Uniti, Canada
-
University of ArkansasOnyx Therapeutics, Inc.Non più disponibile
-
Thomas LundReclutamento
-
Washington University School of MedicineCompletato
-
NovartisAmgenTerminato
-
AmgenMultiple Myeloma Research FoundationApprovato per il marketing
-
AmgenCompletatoMalattia renale allo stadio terminale | Mieloma multiplo recidivatoStati Uniti, Australia, Canada